Abstract
Background and Aims
Epstein-Barr virus (EBV) is present in the malignant epithelial cells of 10% of all gastric adenocarcinomas; however, localization of the virus in normal gastrointestinal mucosa is largely unexplored. In the present study, we measured EBV DNA and localized viral gene products in gastritis specimens (n = 89), normal gastric and colonic mucosa (n = 14), Crohn’s disease (n = 9), and ulcerative colitis (n = 11) tissues.
Methods
A battery of sensitive and specific quantitative polymerase chain reactions targeted six disparate regions of the EBV genome: BamH1 W, EBNA1, LMP1, LMP2, BZLF1, and EBER1. EBV infection was localized by EBV-encoded RNA (EBER) in situ hybridization and by immunohistochemical stains for viral latent proteins LMP1 and LMP2 and for viral lytic proteins BMRF1 and BZLF1. B lymphocytes were identified using CD20 immunostains.
Results
EBV DNA was essentially undetectable in normal gastric mucosa but was present in 46% of gastritis lesions, 44% of normal colonic mucosa, 55% of Crohn’s disease, and 64% of ulcerative colitis samples. Levels of EBV DNA exceeded what would be expected based on the numbers of B lymphocytes in inflamed tissues, suggesting that EBV is preferentially localized to inflammatory gastrointestinal lesions. Histochemical staining revealed EBER expression in lymphoid cells of some PCR-positive lesions. The viral lytic viral proteins, BMRF1 and BZLF1, were expressed in lymphoid cells of two ulcerative colitis tissues, both of which had relatively high viral loads by quantitative PCR.
Conclusion
EBV-infected lymphocytes are frequently present in inflamed gastric and colonic mucosa. Active viral replication in some lesions raises the possibility of virus-related perpetuation of gastrointestinal inflammation.
Similar content being viewed by others
References
Correa P, Piazuelo MB, Camargo MC. The future of gastric cancer prevention. Gastric Cancer. 2004;7:9–16.
Gulley ML, Tang W. Laboratory assays for Epstein-Barr virus-related disease. J Mol Diagn. 2008;10:279–292.
Imai S, Koizumi S, Sugiura M, et al. Gastric carcinoma: Monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein. Proc Natl Acad Sci USA. 1994;91:9131–9135.
Gulley ML, Pulitzer DR, Eagan PA, Schneider BG. Epstein-Barr virus infection is an early event in gastric carcinogenesis and is independent of bcl-2 expression and p53 accumulation. Hum Pathol. 1996;27:20–27.
Zhang Y, Molot R. Severe gastritis secondary to Epstein-Barr viral infection. Unusual presentation of infectious mononucleosis and associated diffuse lymphoid hyperplasia in gastric mucosa. Arch Pathol Lab Med. 2003;127:478–480.
Owens SR, Walls A, Krasinskas AM, Rund CR. Epstein-barr virus gastritis: rare or rarely sampled? A case report. Int J Surg Pathol. 2011;19:196–198.
Toll AD, Malik S, Tuluc M. Ulcerative gastritis secondary to Epstein-Barr viral infection. Dig Dis Sci. 2010;55:218–219.
Kitayama Y, Honda S, Sugimura H. Epstein-Barr virus-related gastric pseudolymphoma in infectious mononucleosis. Gastrointest Endosc. 2000;52:290–291.
Babcock GJ, Decker LL, Freeman RB, Thorley-Lawson DA. Epstein-barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. J Exp Med. 1999;190:567–576.
Dojcinov SD, Venkataraman G, Pittaluga S, et al. Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma. Blood. 2011;117:4726–4735.
Dojcinov SD, Venkataraman G, Raffeld M, Pittaluga S, Jaffe ES. EBV positive mucocutaneous ulcer—a study of 26 cases associated with various sources of immunosuppression. Am J Surg Pathol. 2010;34:405–417.
Schneider BG, Gulley ML, Eagan P, Bravo JC, Mera R, Geradts J. Loss of p16/CDKN2A tumor suppressor protein in gastric adenocarcinoma is associated with Epstein-Barr virus and anatomic location in the body of the stomach. Hum Pathol. 2000;31:45–50.
Arikawa J, Tokunaga M, Tashiro Y, et al. Epstein-Barr virus-positive multiple early gastric cancers and dysplastic lesions: a case report. Pathol Int. 1997;47:730–734.
Yanai H, Takada K, Shimizu N, Mizugaki Y, Tada M, Okita K. Epstein-Barr virus infection in non-carcinomatous gastric epithelium. J Pathol. 1997;183:293–298.
Arikawa J, Tokunaga M, Satoh E, Tanaka S, Land CE. Morphological characteristics of Epstein-Barr virus-related early gastric carcinoma: a case-control study. Pathol Int. 1997;47:360–367.
Hungermann D, Muller S, Spieker T, Lisner R, Niedobitek G, Herbst H. Low prevalence of latently Epstein-Barr virus-infected cells in chronic gastritis. Microsc Res Tech. 2001;53:409–413.
Hirano A, Yanai H, Shimizu N, et al. Evaluation of epstein-barr virus DNA load in gastric mucosa with chronic atrophic gastritis using a real-time quantitative PCR assay. Int J Gastrointest Cancer. 2003;34:87–94.
Fukayama M, Chong JM, Uozaki H. Pathology and molecular pathology of Epstein-Barr virus-associated gastric carcinoma. Curr Top Microbiol Immunol. 2001;258:91–102.
Jing X, Nakamura Y, Nakamura M, et al. Detection of Epstein-Barr virus DNA in gastric carcinoma with lymphoid stroma. Viral Immunol. 1997;10:49–58.
Zur Hausen A, van Rees BP, van Beek J et al. Epstein-Barr virus in gastric carcinomas and gastric stump carcinomas: a late event in gastric carcinogenesis. J Clin Pathol. 2004;57:487–491.
Shukla SK, Prasad KN, Tripathi A, et al. Epstein-Barr virus DNA load and its association with Helicobacter pylori infection in gastroduodenal diseases. Braz J Infect Dis. 2011;15:583–590.
Minoura-Etoh J, Gotoh K, Sato R, et al. Helicobacter pylori-associated oxidant monochloramine induces reactivation of Epstein-Barr virus (EBV) in gastric epithelial cells latently infected with EBV. J Med Microbiol. 2006;55:905–911.
Kojima Y, Mogaki M, Takagawa R, et al. A case of lymphoepithelioma-like carcinoma of the colon with ulcerative colitis. J Gastroenterol. 2007;42:181–185.
Pender MP. Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases. Trends Immunol. 2003;24:584–588.
Vaughan JH, Nguyen MD, Valbracht JR, Patrick K, Rhodes GH. Epstein-Barr virus-induced autoimmune responses. II. Immunoglobulin G autoantibodies to mimicking and nonmimicking epitopes. Presence in autoimmune disease. J Clin Invest. 1995;95:1316–1327.
Harley JB, Harley IT, Guthridge JM, James JA. The curiously suspicious: a role for Epstein-Barr virus in lupus. Lupus. 2006;15:768–777.
Lunemann JD, Munz C. Epstein-Barr virus and multiple sclerosis. Curr Neurol Neurosci Rep. 2007;7:253–258.
Swanson-Mungerson M, Longnecker R. Epstein-Barr virus latent membrane protein 2A and autoimmunity. Trends Immunol. 2007;28:213–218.
Ryan JL, Fan H, Glaser SL, Schichman SA, Raab-Traub N, Gulley ML. Epstein-Barr virus quantization by real-time PCR targeting multiple gene segments: a novel approach to screen for the virus in paraffin-embedded tissue and plasma. J Mol Diagn. 2004;6:378–385.
Ling PD, Vilchez RA, Keitel WA, et al. Epstein-Barr virus DNA loads in adult human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy. Clin Infect Dis. 2003;37:1244–1249.
Glaser SL, Gulley ML, Borowitz MJ, et al. Inter- and intra-observer reliability of Epstein-Barr virus detection in Hodgkin lymphoma using histochemical procedures. Leuk Lymphoma. 2004;45:489–497.
Levine PH, Stemmermann G, Lennette ET, Hildesheim A, Shibata D, Nomura A. Elevated antibody titers to Epstein-Barr virus prior to the diagnosis of Epstein-Barr-virus-associated gastric adenocarcinoma. Int J Cancer.1995;60:642–644.
van Beek J, van Zur Hausen A, Klein Kranenbarg E, et al. EBV-positive gastric adenocarcinomas: a distinct clinicopathologic entity with a low frequency of lymph node involvement. J Clin Oncol. 2004;22:664–670.
Oda K, Koda K, Takiguchi N, Nunomura M, Seike K, Miyazaki M. Detection of Epstein-Barr virus in gastric carcinoma cells and surrounding lymphocytes. Gastric Cancer. 2003;6:173–178.
Luqmani YA, Linjawi SO, Shousha S. Detection of Epstein-Barr virus in gastrectomy specimens. Oncol Rep. 2001;8:995–999.
Nakamura S, Ueki T, Yao T, Ueyama T, Tsuneyoshi M. Epstein-Barr virus in gastric carcinoma with lymphoid stroma. Special reference to its detection by the polymerase chain reaction and in situ hybridization in 99 tumors, including a morphologic analysis. Cancer. 1994;73:2239–2249.
Yuen ST, Chung LP, Leung SY, Luk IS, Chan SY, Ho J. In situ detection of Epstein-Barr virus in gastric and colorectal adenocarcinomas. Am J Surg Pathol. 1994;18:1158–1163.
Morgan DR, Dominguez RL, Keku TO, et al. Gastric cancer and the high combination prevalence of host cytokine genotypes and Helicobacter pylori in Honduras. Clin Gastroenterol Hepatol. 2006;4:1103–1111.
Greenberg ER, Anderson GL, Morgan DR, et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet. 2011;378:507–514.
Cho HJ, Kim JY, Yoo J, Lee SS. Gastric carcinoma with lymphoid stroma: incidence of EBV and Helicobacter pylori infection. Appl Immunohistochem Mol Morphol. 2003;11:149–152.
Normark S, Nilsson C, Normark BH, Hornef MW. Persistent infection with Helicobacter pylori and the development of gastric cancer. Adv Cancer Res. 2003;90:63–89.
Wong NA, Herbst H, Herrmann K, et al. Epstein-Barr virus infection in colorectal neoplasms associated with inflammatory bowel disease: detection of the virus in lymphomas but not in adenocarcinomas. J Pathol. 2003;201:312–318.
Spieker T, Herbst H. Distribution and phenotype of Epstein-Barr virus-infected cells in inflammatory bowel disease. Am J Pathol. 2000;157:51–57.
Wakefield AJ, Fox JD, Sawyerr AM, et al. Detection of herpesvirus DNA in the large intestine of patients with ulcerative colitis and Crohn’s disease using the nested polymerase chain reaction. J Med Virol. 1992;38:183–190.
Gehlert T, Devergne O, Niedobitek G. Epstein-Barr virus (EBV) infection and expression of the interleukin-12 family member EBV-induced gene 3 (EBI3) in chronic inflammatory bowel disease. J Med Virol. 2004;73:432–438.
Ruther U, Nunnensiek C, Muller HA, Bader H, May U, Jipp P. Interferon alpha (IFN alpha 2a) therapy for herpes virus-associated inflammatory bowel disease (ulcerative colitis and Crohn’s disease). Hepatogastroenterology. 1998;45:691–699.
Yanai H, Shimizu N, Nagasaki S, Mitani N, Okita K. Epstein-Barr virus infection of the colon with inflammatory bowel disease. Am J Gastroenterol. 1999;94:1582–1586.
Marszalek A, Marciniak R, Szkaradkiewicz A, et al. Inflammatory bowel disease—is there something new in the immunological background? Folia Histochem Cytobiol. 2011;49:357–362.
Maher MM, Nassar MI. Acute cytomegalovirus infection is a risk factor in refractory and complicated inflammatory bowel disease. Dig Dis Sci. 2009;54:2456–2462.
Sipponen T, Turunen U, Lautenschlager I, Nieminen U, Arola J, Halme L. Human herpesvirus 6 and cytomegalovirus in ileocolonic mucosa in inflammatory bowel disease. Scand J Gastroenterol. 2011;46:1324–1333.
Baumann MA, Paul CC. Interleukin-5 is an autocrine growth factor for Epstein-Barr virus-transformed B lymphocytes. Blood. 1992;79:1763–1767.
Tosato G, Tanner J, Jones KD, Revel M, Pike SE. Identification of interleukin-6 as an autocrine growth factor for Epstein-Barr virus-immortalized B cells. J Virol. 1990;64:3033–3041.
Mauser A, Holley-Guthrie E, Zanation A, et al. The Epstein-Barr virus immediate-early protein BZLF1 induces expression of E2F–1 and other proteins involved in cell cycle progression in primary keratinocytes and gastric carcinoma cells. J Virol. 2002;76:12543–12552.
Israel BF, Kenney SC. Virally targeted therapies for EBV-associated malignancies. Oncogene. 2003;22:5122–5130.
Kenney S, Theodore E. Woodward award: development of novel, EBV-targeted therapies for EBV-positive tumors. Trans Am Clin Climatol Assoc. 2006;117:55–74.
Foxman EF, Iwasaki A. Genome-virome interactions: examining the role of common viral infections in complex disease. Nat Rev Microbiol. 2011;9:254–264.
Young VB. The intestinal microbiota in health and disease. Curr Opin Gastroenterol. 2012;28:63–69.
Chai H, Brown RE. Field effect in cancer-an update. Ann Clin Lab Sci. 2009;39:331–337.
Meckes DG Jr, Raab-Traub N. Microvesicles and viral infection. J Virol. 2011;85:12844–12854.
Pegtel DM, van de Garde MD, Middeldorp JM. Viral miRNAs exploiting the endosomal-exosomal pathway for intercellular cross-talk and immune evasion. Biochim Biophys Acta. 1809;2011:715–721.
Acknowledgments
The authors thank Sandra Elmore for technical assistance. This study was funded by the University of North Carolina Department of Pathology and Laboratory Medicine with support from the National Institutes of Health: Environmental Pathology Training Grant (T32-ES07017) supporting graduate studies of Julie L. Ryan, PhD, MPH, Cancer Epidemiology Award (K07CA125588) and funds for the UNC Center for Gastrointestinal Biology and Disease (P30 DK 034987) supporting Douglas R. Morgan, MD MPH, and the Alliance for Clinical Trials in Oncology (U10 CA031946), Clinical Translational Science Award (U54 RR024383), and Innovative Technologies for Molecular Analysis of Cancer (R21 CA155543) award supporting Margaret L. Gulley, MD.
Conflict of interest
MLG is a consultant for McKesson, Abbott Laboratories, and Roche Molecular Systems, and serves on the clinical advisory board of Generation Health.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ryan, J.L., Shen, YJ., Morgan, D.R. et al. Epstein-Barr Virus Infection Is Common in Inflamed Gastrointestinal Mucosa. Dig Dis Sci 57, 1887–1898 (2012). https://doi.org/10.1007/s10620-012-2116-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-012-2116-5